etylmetylhydroksypyrydyna | Mexidol ampoules 5%, 2 ml, 10 pcs.

Release form

Solution for iv and intramuscular administration colorless or slightly yellowish, transparent.

Packing

10 ampoules of 2 ml each

Pharmacological action

Pharmacodynamics

Mexidol® has an antihypoxic effect membrane-protective, nootropic, anticonvulsant, anxiolytic effects, increases the body's resistance to stress. The drug increases the body's resistance to the effects of the main damaging factors, to oxygen-dependent pathological conditions (shock, hypoxia and ischemia, cerebrovascular accident, intoxication with alcohol and antipsychotic drugs (antipsychotics)).

Mexidol® improves cerebral metabolism and blood supply to the brain, improves microcirculation and rheological properties of blood, and reduces platelet aggregation. It stabilizes the membrane structures of blood cells (red blood cells and platelets) during hemolysis. It has a lipid-lowering effect, reduces the level of total cholesterol and LDL. Reduces enzymatic toxemia and endogenous intoxication in acute pancreatitis.

The mechanism of action of Mexidol® is due to its antihypoxant, antioxidant and membrane-protective action. It inhibits lipid peroxidation processes, increases the activity of superoxide dismutase, increases the lipid-protein ratio, reduces the viscosity of the membrane, and increases its fluidity. It modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, helps preserve the structural and functional organization of biomembranes and transport. Mexidol® increases dopamine in the brain. It causes an increase in the compensatory activity of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under conditions of hypoxia, with an increase in the content of ATP, creatine phosphate and activation of the energy-synthesizing functions of mitochondria, stabilization of cell membranes.

Mexidol® normalizes metabolic processes in the ischemic myocardium, reduces the necrosis zone, restores and improves electrical activity and myocardial contractility, as well as increases coronary blood flow in the ischemic zone, and reduces the effects of reperfusion syndrome in acute coronary insufficiency. Increases antianginal activity of nitro drugs.

Mexidol® contributes to the preservation of ganglion cells of the retina and optic nerve fibers with progressive neuropathy, the causes of which are chronic ischemia and hypoxia. Improves the functional activity of the retina and optic nerve, increasing visual acuity.

Pharmacokinetics

Absorption

With the introduction of Mexidol® in doses of 400-500 mg Cmax in plasma is 3.5-4.0 μg / ml and is achieved within 0.45-0.5 hours.

Distribution of

After i / m administration, the drug is determined in blood plasma for 4 hours. The average retention time of the drug in the body is 0.7-1.3 hours.

Excretion

It is excreted in the urine mainly in a glucuronoconjugated form and in insignificant amounts unchanged.

Indications

acute cerebrovascular accident

head injury, consequences of traumatic brain injuries

discirculatory encephalopathy

autonomic dystonia syndrome

mild cognitive impairment of atherosclerotic genesis

anxiety disorders in neurotic and neurosis-like states

acute myocardial infarction in the first day of treatment)

relief of withdrawal symptoms in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders

acute intoxication with antipsychotic agents

acute purulent-inflammatory processes of the abdominal cavity (acute necrotic pancreatitis, peritonitis) as part of complex therapy.

Contraindications

increased individual sensitivity to the drug

acute impairment of liver and kidney function.

Strictly controlled clinical trials of the safety of using MexidolВ® in children, during pregnancy and lactation have not been conducted.

Pregnancy and lactation

There have been no strictly controlled clinical trials of the safety of Mexidol® during pregnancy and lactation.

Special instructions

Mexidol can be combined with all drugs used to treat somatic diseases.

Pediatric use

There have been no strictly controlled clinical trials of the safety of the drug MexidolВ® in children. In some cases, especially in susceptible patients with bronchial asthma with increased sensitivity to sulfites, severe hypersensitivity reactions may develop.

Effect on the ability to drive vehicles and control mechanisms

During treatment, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.

In some cases, especially in predisposed patients with bronchial asthma with increased sensitivity to sulfites, the development of severe hypersensitivity reactions is possible.

Composition

1 ml solution contains:

Active ingredient:

ethylmethylhydroxypyridine succinate 50 mg

Excipients:

sodium metabisulfite - 0.4 mg,

water d / i - up to 1 ml.

Dosage and administration of

i / m or iv (jet or drip). With the infusion method of administration, the drug should be diluted in a 0.9% sodium chloride solution.

Jetno Mexidol® is administered slowly for 5 to 7 minutes, drip at a rate of 40 to 60 drops per minute. The maximum daily dose should not exceed 1200 mg.

In case of acute cerebrovascular accident, Mexidol® is used in the first 10-14 days - iv drip 200-500 mg 2-4 times a day, then IM 200-250 mg 2-3 times a day for 2 weeks.

In case of traumatic brain injury and the consequences of traumatic brain injury, Mexidol® is used intravenously in a drip of 200 - 500 mg 2-4 times a day for 10 to 15 days.

In case of dyscirculatory encephalopathy in the decompensation phase, Mexidol® should be given iv in a drop or drop dose of 200-500 mg 1-2 times a day for 14 days. Then i / m at 100 - 250 mg / day for the next 2 weeks.

For the course of prophylaxis of dyscirculatory encephalopathy, the drug is administered intramuscularly at a dose of 200 - 250 mg 2 times a day for 10 to 14 days.

In case of mild cognitive impairment in elderly patients and anxiety disorders, the drug is used IM in a daily dose of 100-300 mg / day. for 14 to 30 days.

In acute myocardial infarction as part of complex therapy, Mexidol® is administered intravenously or intramuscularly for 14 days, against the background of traditional therapy for myocardial infarction, including nitrates, beta-blockers, angiotensin converting enzyme inhibitors (ACEs), thrombolytics, anticoagulant and anticoagulant agents symptomatic remedies according to indications.

In the first 5 days, to achieve maximum effect, it is advisable to administer the drug intravenously, in the next 9 days, Mexidol® can be administered intramuscularly.

Intravenous administration of the drug is carried out by drop infusion, slowly (to avoid side effects) in a 0.9% sodium chloride solution or 5% dextrose (glucose) solution in a volume of 100 - 150 ml for 30 - 90 minutes. If necessary, slow injection of the drug is possible, lasting at least 5 minutes.

The introduction of the drug (intravenous or intramuscular) is carried out 3 times a day, every 8 hours. The daily therapeutic dose is 6 - 9 mg / kg body weight per day, a single dose is 2 - 3 mg / kg body weight. The maximum daily dose should not exceed 800 mg, a single - 250 mg.

With open-angle glaucoma of various stages, Mexidol® is administered intramuscularly at 100-300 mg / day, 1-3 times a day for 14 days as part of the complex therapy.

With withdrawal alcohol syndrome, Mexidol® is administered at a dose of 200 - 500 mg iv / drop or IM 2 - 3 times a day for 5 - 7 days.

In acute intoxication with antipsychotics, the drug is administered iv in a dose of 200-500 mg / day for 7-14 days.

In acute purulent-inflammatory processes of the abdominal cavity (acute necrotic pancreatitis, peritonitis), the drug is prescribed on the first day both in the preoperative and postoperative period. The doses administered depend on the form and severity of the disease, the prevalence of the process, and options for the clinical course. Discontinuation of the drug should be done gradually only after a steady positive clinical and laboratory effect.

In acute edematous (interstitial) pancreatitis, Mexidol® is prescribed 200–500 mg 3 times a day, iv / drop (in 0.9% sodium chloride solution) and / m. Mild severity of necrotic pancreatitis - 100-200 mg 3 times a day in / drip (in 0.9% sodium chloride solution) and / m. The average severity is 200 mg 3 times a day, in / drip (in 0.9% sodium chloride solution). Severe course - in a pulse dosage of 800 mg on the first day, with a double regimen of administration, then 200 to 500 mg 2 times a day with a gradual decrease in the daily dose. Extremely severe course - at an initial dosage of 800 mg / day until persistent relief of manifestations of pancreatogenic shock, to stabilize the state of 300 - 500 mg 2 times a day in / drip (in 0.9% sodium chloride solution) with a gradual decrease in the daily dosage.

Side effects of the

Digestive system: rarely - nausea, dry mouth.

Other: rarely - allergic reactions.

Drug interaction

When combined, Mexidol® enhances the action of anxiolytics of benzodiazepine derivatives, antiparkinsonian (levodopa) and anticonvulsant (carbamazepine) drugs.

Mexidol® reduces the toxic effects of ethyl alcohol.

Overdose

Symptoms: possible drowsiness.

Storage Conditions

In a dry, dark place out of the reach of children, at a temperature not exceeding 25 РC.

Shelf life

3 years. Do not use after the expiration date indicated on the package

Deystvuyushtee substance

Эtilmetilgidroksipiridina succinate

Conditions of dispatch from

pharmacies Prescription of

dosage form

injection and infusion

Prescribed f

Prescribing

Adults as prescribed by the doctor

Pharmasoft, Russia